Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients

Zhou, Lulu; Xu, Xiaohui; Liu, Hailing; Hu, Xiaoli; Zhang, Wenwen; Ye, Miaomiao; Zhu, Xueqiong

doi:10.7150/jca.26780



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2018; 9(23):4547-4555. doi:10.7150/jca.26780 This issue Cite

Research Paper

Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients

Lulu Zhou, Xiaohui Xu, Hailing Liu, Xiaoli Hu, Wenwen Zhang, Miaomiao Ye, Xueqiong Zhu^✉

Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China.

Citation:

Zhou L, Xu X, Liu H, Hu X, Zhang W, Ye M, Zhu X. Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients. J Cancer 2018; 9(23):4547-4555. doi:10.7150/jca.26780. https://www.jcancer.org/v09p4547.htm

Other styles

Abstract

Histone deacetylases modulate the dynamic balance of histone acetylation and deacetylation in cells, which participate in epigenetic regulations. Accumulated evidence has demonstrated that histone deacetylases are associated with angiogenesis, cell proliferation and survival in a variety of human cancers. However, the expression and distinct prognostic value of histone deacetylases in ovarian cancer have not been well elucidated. In the present study, we collected the overall survival (OS), progress free survival (PFS), and histone deacetylases (HDAC1-11) mRNA expression in ovarian cancer from the Kaplan-Meier plotter online database. We investigated the relationship between histone deacetylases mRNA level and the clinicopathological parameters of the ovarian cancer patients, such as histology subtypes, clinical stages, grades and TP53 mutation. Our analysis data showed that over-expression of HDAC1, HDAC2, HDAC4, HDAC5 and HDAC11 were correlated to poor overall survival and unfavorable progress free survival in all ovarian cancer patients. Notably, the higher level of HDAC11 was associated with the worse OS and PFS for serous/ stage III+IV/ grade III/ TP53 mutation ovarian cancer patients. In conclusion, HDACs may play a crucial role in the prognosis of ovarian cancer, but it is worth noting that HDAC11 may be a biomarker for poor prognosis in ovarian cancer patients.

Keywords: ovarian cancer, prognosis, HDACs, Kaplan-Meier plotter

Citation styles

APA

Zhou, L., Xu, X., Liu, H., Hu, X., Zhang, W., Ye, M., Zhu, X. (2018). Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients. Journal of Cancer, 9(23), 4547-4555. https://doi.org/10.7150/jca.26780.

ACS

Zhou, L.; Xu, X.; Liu, H.; Hu, X.; Zhang, W.; Ye, M.; Zhu, X. Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients. J. Cancer 2018, 9 (23), 4547-4555. DOI: 10.7150/jca.26780.

NLM

CSE

Zhou L, Xu X, Liu H, Hu X, Zhang W, Ye M, Zhu X. 2018. Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients. J Cancer. 9(23):4547-4555.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.